Human Xtensions Ltd. is a medical technology company that develops, manufactures, and commercializes handheld robotic and electromechanical surgical systems for minimally invasive surgery. Founded in 2012 and headquartered in Netanya, Israel, the company specializes in digital surgical solutions designed to combine the dexterity and precision of robotic surgical systems with the affordability, ease of use, and accessibility of standard laparoscopic instruments. The company operates primarily through the development and sale of its proprietary HandX platform, serving general surgery, bariatric, gynecological, urological, and colorectal surgical specialties across hospitals, academic medical centers, and ambulatory surgical facilities globally. Human Xtensions Ltd. offers a comprehensive portfolio of smart surgical instruments and accessories, including the HandX Drive Unit, a reusable, ergonomically motorized handheld robotic controller; the HandX Needle Holder, an articulating instrument providing multi-degree-of-freedom wristing for intracorporeal suturing; the HandX Monopolar Scissors, providing precision electrosurgical cutting and dissection; the HandX Bipolar Forceps, designed for tissue manipulation and controlled coagulation; the HandX Monopolar Hook, facilitating delicate tissue dissection; the HandX Clip Applier, enabling vessel and tissue ligation; and sterile single-use articulating instrument tips, adaptors, and sterile drapes. The company commercializes its products across international healthcare markets, including the United States, Europe, Israel, and the Asia-Pacific region, utilizing a hybrid model of direct sales forces and specialized third-party medical device distributors. In recent developments, Human Xtensions Ltd. has expanded its international commercial reach through new distribution agreements in Europe and North America; secured regulatory milestone clearances, including expanded United States Food and Drug Administration (FDA) 510(k) clearances and European CE Mark certifications for its next-generation articulating electrosurgical instruments; broadened the HandX platform capabilities to support advanced robotic-assisted laparoscopic interventions; instituted corporate restructuring and operational efficiency programs to optimize manufacturing and commercialization; and completed capital financing initiatives on the Tel Aviv Stock Exchange to support global market adoption, clinical registry studies, and ongoing research and development.